Momenta Pharmaceuticals, Inc. (MNTA)

[oldberkeley]

After today's Teva presentation I'm starting to favor choice #2.

I know that you're joking about "starting over", but I think that whatever news the FDA delivers, it won't be good for Teva.

As long as the media/analysts/whomever spins this news in a reasonably truthful and accurate manner (the best we can hope for) things should be looking up for MNTA.

Best of luck.

Addendum: I just read poorgradstudent's post on the BV board, he's expecting Teva to get a "to-do list" from the FDA in January.